Trade Applied Therapeutics, Inc. - APLT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0178 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Applied Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 2.4661 |
| Open* | 2.4761 |
| 1-Year Change* | 173.42% |
| Day's Range* | 2.2661 - 2.4761 |
| 52 wk Range | 0.70-3.11 |
| Average Volume (10 days) | 639.26K |
| Average Volume (3 months) | 21.04M |
| Market Cap | 152.91M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 77.23M |
| Revenue | 10.66M |
| EPS | -1.31 |
| Dividend (Yield %) | N/A |
| Beta | 1.42 |
| Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 5, 2023 | 2.2761 | -0.1800 | -7.33% | 2.4561 | 2.5061 | 2.2561 |
| Dec 4, 2023 | 2.4661 | 0.0600 | 2.49% | 2.4061 | 2.5561 | 2.3761 |
| Dec 1, 2023 | 2.3961 | 0.2800 | 13.23% | 2.1161 | 2.4361 | 2.0761 |
| Nov 30, 2023 | 2.0961 | 0.1500 | 7.71% | 1.9461 | 2.1861 | 1.9461 |
| Nov 29, 2023 | 1.9961 | 0.0500 | 2.57% | 1.9461 | 2.0761 | 1.9461 |
| Nov 28, 2023 | 1.9261 | 0.1100 | 6.06% | 1.8161 | 1.9461 | 1.7961 |
| Nov 27, 2023 | 1.8361 | -0.0100 | -0.54% | 1.8461 | 1.8761 | 1.7861 |
| Nov 24, 2023 | 1.7961 | -0.0800 | -4.26% | 1.8761 | 1.9561 | 1.7861 |
| Nov 22, 2023 | 1.8961 | -0.0400 | -2.07% | 1.9361 | 1.9961 | 1.8761 |
| Nov 21, 2023 | 1.9561 | -0.0400 | -2.00% | 1.9961 | 2.0461 | 1.9161 |
| Nov 20, 2023 | 1.9861 | 0.1300 | 7.00% | 1.8561 | 2.0961 | 1.8461 |
| Nov 17, 2023 | 1.9661 | 0.0400 | 2.08% | 1.9261 | 2.0061 | 1.8661 |
| Nov 16, 2023 | 1.9561 | -0.1700 | -8.00% | 2.1261 | 2.1261 | 1.8561 |
| Nov 15, 2023 | 2.1261 | 0.1000 | 4.94% | 2.0261 | 2.2261 | 2.0061 |
| Nov 14, 2023 | 2.0461 | 0.1600 | 8.48% | 1.8861 | 2.0861 | 1.8861 |
| Nov 13, 2023 | 1.9261 | -0.0700 | -3.51% | 1.9961 | 2.0161 | 1.8161 |
| Nov 10, 2023 | 2.0061 | -0.0500 | -2.43% | 2.0561 | 2.1061 | 1.9361 |
| Nov 9, 2023 | 2.0561 | -0.2400 | -10.45% | 2.2961 | 2.3061 | 1.7961 |
| Nov 8, 2023 | 2.3061 | -0.1100 | -4.55% | 2.4161 | 2.5061 | 2.2961 |
| Nov 7, 2023 | 2.4461 | 0.1100 | 4.71% | 2.3361 | 2.4461 | 2.2761 |
Applied Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 21, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 Applied Therapeutics Inc Earnings Release Q4 2023 Applied Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 82.95 | 105.618 | 94.466 | 45.582 | 13.739 |
| Selling/General/Admin. Expenses, Total | 27.316 | 43.048 | 32.678 | 13.232 | 2.047 |
| Research & Development | 55.634 | 62.57 | 61.788 | 32.35 | 11.471 |
| Unusual Expense (Income) | 0 | 0.221 | |||
| Operating Income | -82.95 | -105.618 | -94.466 | -45.582 | -13.739 |
| Interest Income (Expense), Net Non-Operating | 0.685 | 0.555 | 0.559 | 0.093 | -2.782 |
| Net Income Before Taxes | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Net Income After Taxes | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Net Income Before Extra. Items | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Net Income | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Income Available to Common Excl. Extra. Items | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Income Available to Common Incl. Extra. Items | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Diluted Net Income | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Diluted Weighted Average Shares | 37.8254 | 25.5982 | 21.9663 | 12.8312 | 17.0522 |
| Diluted EPS Excluding Extraordinary Items | -2.18128 | -4.12467 | -4.2775 | -3.54705 | -0.96885 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -2.18128 | -4.12467 | -4.2775 | -3.54705 | -0.95589 |
| Other, Net | -0.243 | -0.521 | -0.054 | -0.024 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 10.66 | 0 | 0 | 0 |
| Total Operating Expense | 17.176 | 21.518 | 18.972 | 19.356 | 21.521 |
| Selling/General/Admin. Expenses, Total | 5.293 | 5.583 | 6.88 | 6.24 | 6.125 |
| Research & Development | 11.883 | 15.935 | 12.092 | 13.116 | 15.396 |
| Operating Income | -17.176 | -10.858 | -18.972 | -19.356 | -21.521 |
| Interest Income (Expense), Net Non-Operating | 0.408 | 0.221 | 0.271 | 0.227 | 0.111 |
| Other, Net | -12.809 | 0.5 | 4.272 | 0.028 | -4.447 |
| Net Income Before Taxes | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Net Income After Taxes | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Net Income Before Extra. Items | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Net Income | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Income Available to Common Excl. Extra. Items | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Income Available to Common Incl. Extra. Items | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Diluted Net Income | -29.577 | -10.137 | -14.429 | -19.101 | -25.857 |
| Diluted Weighted Average Shares | 79.0417 | 56.358 | 49.9456 | 48.0002 | 26.9011 |
| Diluted EPS Excluding Extraordinary Items | -0.37419 | -0.17987 | -0.28889 | -0.39794 | -0.96119 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.37419 | -0.17987 | -0.28889 | -0.39794 | -0.96119 |
| Revenue | 0 | 10.66 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 37.308 | 88.394 | 102.593 | 46.155 | 20.246 |
| Cash and Short Term Investments | 30.58 | 80.823 | 96.829 | 38.854 | 18.748 |
| Cash & Equivalents | 16.657 | 53.888 | 57.466 | 18.85 | 18.748 |
| Prepaid Expenses | 6.728 | 7.571 | 5.764 | 7.301 | 1.198 |
| Total Assets | 38.363 | 89.892 | 104.506 | 48.389 | 20.246 |
| Total Current Liabilities | 33.424 | 26.462 | 21.235 | 14.099 | 4.428 |
| Accounts Payable | 4.534 | 9.461 | 0.64 | 8.793 | 3.015 |
| Accrued Expenses | 15.233 | 16.014 | 20.042 | 5.042 | 1.413 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 34.302 | 27.353 | 22.567 | 15.782 | 4.428 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 4.061 | 62.539 | 81.939 | 32.607 | 15.818 |
| Preferred Stock - Non Redeemable, Net | 0 | 35.41 | |||
| Common Stock | 0.005 | 0.003 | 0.002 | 0.001 | 0 |
| Additional Paid-In Capital | 352.828 | 328.958 | 242.78 | 99.378 | 1.665 |
| Retained Earnings (Accumulated Deficit) | -348.823 | -266.315 | -160.731 | -66.77 | -21.257 |
| Total Liabilities & Shareholders’ Equity | 38.363 | 89.892 | 104.506 | 48.389 | 20.246 |
| Total Common Shares Outstanding | 48.0634 | 26.2155 | 22.4937 | 18.5316 | 17.0522 |
| Other Current Assets, Total | 0 | 0.3 | |||
| Short Term Investments | 13.923 | 26.935 | 39.363 | 20.004 | |
| Property/Plant/Equipment, Total - Net | 0.857 | 1.298 | 1.712 | 2.035 | |
| Other Long Term Assets, Total | 0.198 | 0.2 | 0.201 | 0.199 | |
| Other Current Liabilities, Total | 13.657 | 0.987 | 0.553 | 0.264 | |
| Other Liabilities, Total | 0.878 | 0.891 | 1.332 | 1.683 | |
| Other Equity, Total | 0.051 | -0.107 | -0.112 | -0.002 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 44.488 | 42.821 | 29.063 | 37.308 | 55.51 |
| Cash and Short Term Investments | 37.457 | 35.616 | 22.917 | 30.58 | 47.378 |
| Cash & Equivalents | 37.457 | 35.616 | 22.917 | 16.657 | 40.388 |
| Short Term Investments | 0 | 0 | 0 | 13.923 | 6.99 |
| Prepaid Expenses | 7.031 | 7.205 | 6.146 | 6.728 | 8.132 |
| Total Assets | 45.195 | 43.646 | 30.004 | 38.363 | 56.679 |
| Property/Plant/Equipment, Total - Net | 0.51 | 0.628 | 0.743 | 0.857 | 0.97 |
| Other Long Term Assets, Total | 0.197 | 0.197 | 0.198 | 0.198 | 0.199 |
| Total Current Liabilities | 55.504 | 47.188 | 33.251 | 33.424 | 46.514 |
| Accounts Payable | 6.005 | 4.687 | 5.555 | 4.534 | 6.973 |
| Accrued Expenses | 12.736 | 16.509 | 14.508 | 15.233 | 14.344 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 36.763 | 25.992 | 13.188 | 13.657 | 25.197 |
| Total Liabilities | 56.239 | 47.98 | 34.076 | 34.302 | 47.05 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.735 | 0.792 | 0.825 | 0.878 | 0.536 |
| Total Equity | -11.044 | -4.334 | -4.072 | 4.061 | 9.629 |
| Common Stock | 0.007 | 0.006 | 0.005 | 0.005 | 0.005 |
| Additional Paid-In Capital | 419.856 | 384.197 | 354.883 | 352.828 | 343.995 |
| Retained Earnings (Accumulated Deficit) | -430.907 | -388.537 | -358.96 | -348.823 | -334.394 |
| Other Equity, Total | 0 | 0 | 0 | 0.051 | 0.023 |
| Total Liabilities & Shareholders’ Equity | 45.195 | 43.646 | 30.004 | 38.363 | 56.679 |
| Total Common Shares Outstanding | 77.1335 | 62.1195 | 48.1136 | 48.0634 | 48.059 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 |
| Cash From Operating Activities | -78.093 | -90.728 | -78.209 | -36.307 | -11.182 |
| Non-Cash Items | 13.699 | 15.874 | 10.956 | 5.995 | 3.275 |
| Changes in Working Capital | -9.286 | -1.018 | 4.796 | 3.211 | 2.064 |
| Cash From Financing Activities | 27.692 | 74.717 | 136.294 | 56.415 | 26.653 |
| Financing Cash Flow Items | 3.105 | 4.434 | 2.523 | 16.012 | -0.119 |
| Issuance (Retirement) of Stock, Net | 27.86 | 75.001 | 135.919 | 40.403 | 21.212 |
| Issuance (Retirement) of Debt, Net | -3.273 | -4.718 | -2.148 | 0 | 5.56 |
| Net Change in Cash | -37.231 | -3.578 | 38.616 | 0.102 | 15.471 |
| Cash From Investing Activities | 13.17 | 12.433 | -19.469 | -20.006 | |
| Other Investing Cash Flow Items, Total | 13.17 | 12.433 | -19.469 | -20.006 | |
| Cash From Operating Activities | 0.002 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.137 | -82.508 | -68.079 | -48.978 | -23.121 |
| Cash From Operating Activities | -6.99 | -78.093 | -62.2 | -42.81 | -24.41 |
| Non-Cash Items | 2.466 | 13.699 | 15.06 | 11.347 | 3.719 |
| Changes in Working Capital | 0.681 | -9.286 | -9.182 | -5.18 | -5.008 |
| Cash From Investing Activities | 13.872 | 13.17 | 20.075 | 15.054 | 9.525 |
| Other Investing Cash Flow Items, Total | 13.872 | 13.17 | 20.075 | 15.054 | 9.525 |
| Cash From Financing Activities | -0.622 | 27.692 | 28.625 | 29.596 | -0.789 |
| Issuance (Retirement) of Stock, Net | 27.86 | 27.86 | 27.899 | 0 | |
| Issuance (Retirement) of Debt, Net | -0.622 | -3.273 | -2.34 | -1.408 | -0.789 |
| Net Change in Cash | 6.26 | -37.231 | -13.5 | 1.84 | -15.674 |
| Financing Cash Flow Items | 3.105 | 3.105 | 3.105 | ||
| Cash From Operating Activities | 0.002 | 0.001 | 0.001 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 12.589 | 7946732 | 0 | 2023-06-30 | LOW |
| VR Adviser, LLC | Venture Capital | 8.9633 | 5658034 | 0 | 2023-06-30 | MED |
| Armistice Capital LLC | Hedge Fund | 8.4499 | 5333951 | 5333951 | 2022-12-31 | MED |
| Shendelman (Shoshana) | Individual Investor | 7.9956 | 5047165 | -115632 | 2023-09-27 | LOW |
| Propel Bio Partners L.P. | Venture Capital | 7.5365 | 4757382 | 3522863 | 2023-02-28 | HIGH |
| Alexandria Real Estate Equities, Inc. | Investment Advisor | 7.2161 | 4555077 | 1121023 | 2022-06-27 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 7.0201 | 4431406 | 3632304 | 2023-06-30 | HIGH |
| Knoll Capital Management, LLC | Hedge Fund | 5.4654 | 3450000 | 0 | 2023-06-30 | |
| Fidelity Management & Research Company LLC | Investment Advisor | 4.1815 | 2639536 | -332835 | 2023-06-30 | LOW |
| Simplify Asset Management Inc | Investment Advisor | 3.7745 | 2382621 | 0 | 2023-06-30 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.5794 | 997002 | 141847 | 2023-06-30 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 1.2369 | 780791 | 0 | 2023-06-30 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 0.7524 | 474929 | -245009 | 2023-06-30 | HIGH |
| Marcus (Joel S) | Individual Investor | 0.7183 | 453414 | 12375 | 2023-09-15 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6978 | 440505 | 79427 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.6454 | 407378 | 187578 | 2023-06-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6192 | 390838 | 123521 | 2023-06-30 | LOW |
| Laurion Capital Management LP | Hedge Fund | 0.548 | 345900 | 0 | 2023-06-30 | HIGH |
| CM Management, LLC | Investment Advisor | 0.4753 | 300000 | 300000 | 2023-06-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.2079 | 131225 | -107711 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Applied Therapeutics, Inc. Company profile
About Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Applied Therapeutics Inc revenues was not reported. Net loss increased 12% to $105.6M. Higher net loss reflects General and administrative - Balancing increase of 66% to $15.7M (expense), Stock-based Compensation in SGA increase of 55% to $8.4M (expense), Other general & administrative expenses increase of 73% to $5.4M (expense).
| Industry: | Bio Therapeutic Drugs |
545 5Th Avenue, Suite 1400
NEW YORK
NEW YORK 10017
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com